List view / Grid view
5 November 2015 | By Victoria White
GlobalData says this rise will be driven primarily by the introduction of novel drugs, most notably Shire’s lifitegrast, a first-in-class drug with anti-inflammatory benefits...
29 October 2015 | By Victoria White
The global multiple myeloma treatment market will rise in value from $8.9 billion in 2014 to an estimated $22.4 billion by 2023, according to research and consulting firm GlobalData...
23 October 2015 | By Victoria White
GlobalData says this increase will be driven by the modest uptake of patent-protected, Clostridium difficile infection-specific antibiotics and the arrival of novel non-antibiotic approaches...
19 October 2015 | By Victoria White
The global treatment market for peripheral artery disease will hit a peak of $983.6 million in 2020, before falling to $816.3 million by 2024 due to the generic erosion of Brilinta and Xarelto...
7 October 2015 | By Victoria White
The value of the multiple sclerosis therapeutics market will rise slowly from $17.2 billion in 2014 to approximately $20 billion by 2024...
17 September 2015 | By Victoria White
The value of the global therapeutics market for benign prostatic hyperplasia will rise from $2 billion in 2014 to approximately $4.9 billion by 2024...
9 September 2015 | By Victoria White
The value of the global treatment market for allergic rhinitis will witness minimal growth from $7.2 billion in 2014 to $7.3 billion by 2024, says research and consulting firm GlobalData...
25 August 2015 | By Victoria White
Brazil's pharmaceutical market will expand to reach approximately $47.9 billion by 2020, according to research and consulting firm GlobalData...
The global market for growth hormone deficiency (GHD) treatment will rise in value from $1.26 billion in 2014 to reach approximately $1.88 billion by 2024, representing a moderate Compound Annual Growth Rate (CAGR) of 4.08%, according to research and consulting firm GlobalData.
6 August 2015 | By Victoria White
The global treatment market for Fabry disease will expand in value from $683 million in 2014 to approximately $1.25 billion by 2024...
28 July 2015 | By Victoria White
Atezolizumab is poised to become a major bladder cancer therapy in the race for FDA approval, following its promising performance in recent Phase II trials...
22 July 2015 | By Victoria White
Stelara has progressed into Phase III development for axSpA and, following its anticipated approval, is forecast to achieve sales of $244.7 million in 2024...
21 July 2015 | By Victoria White
The global market value for genital herpes therapeutics will increase from approximately $490 million in 2013 to just under $668 million by 2023, largely driven by the introduction of therapeutic vaccines, HerpV and GEN-003, towards the end of the forecast period, says research and consulting firm GlobalData.
14 July 2015 | By Victoria White
The global market for myasthenia gravis therapeutics is anticipated to more than treble in value from $146.4 million in 2014 to $550.4 million by 2024...
2 July 2015 | By Victoria White
The Parkinson’s disease treatment market value across eight major countries will reach $4.7 billion by 2022, says GlobalData...
